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Abstract
Rationale There is an unmet need in the treatment of
schizophrenia for effective medications with fewer adverse
effects.
Objective This study aims to evaluate the efficacy and safe-
ty of lurasidone, an atypical antipsychotic, for the treatment
of schizophrenia.
Methods Patients with an acute exacerbation of schizophre-
nia were randomized to 6 weeks of double-blind treatment
with once-daily, fixed-dose lurasidone 40 mg (N050), lur-
asidone 120 mg (N049), or placebo (N050). The primary
efficacy measure was mean change from baseline to day 42
(last observation carried forward) in the Brief Psychiatric
Rating Scale derived (BPRSd) from the Positive and Nega-
tive Syndrome Scale (PANSS).
Results Mean change in BPRSd was significantly greater in
patients receiving lurasidone 40 and 120 mg/day versus pla-
cebo (−9.4 and −11.0 versus −3.8; p00.018 and 0.004, re-
spectively). Treatment with lurasidone 120 mg/day was
superior to placebo across all secondary measures, including
PANSS total (p00.009), PANSS positive (p00.005), PANSS
negative (p00.011), and PANSS general psychopathology
(p00.023) subscales and Clinical Global Impression of Se-
verity (CGI-S; p00.001). Treatment with lurasidone 40 mg/
day was superior to placebo on the PANSS positive subscale
(p00.018) and CGI-S (p00.002). The most common adverse
events for patients receiving lurasidone were nausea (16.2
versus 4.0 % for placebo) and sedation (16.2 versus 10.0 %
for placebo). Minimal changes in weight, cholesterol, triglyc-
eride, and glucose levels were observed.
Conclusions In this study, which was limited by a relatively
high discontinuation rate, lurasidone provided effective
treatment for patients with acute exacerbation of chronic
schizophrenia and had minimal effects on weight and met-
abolic parameters.
Keywords Lurasidone . Schizophrenia . Atypical
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Introduction
Schizophrenia is a chronic and debilitating psychiatric dis-
order that affects an estimated 1 % of the adult population
(Regier et al. 1993). Although improvement is noted over
time for some patients, the majority of patients experience at
least some persisting symptoms despite treatment (Regier et
al. 1993). The annual cost of schizophrenia in the USA is
estimated as $63 billion with about $23 billion attributable
to direct healthcare costs (Wu et al. 2005).
Although first-generation or conventional antipsychotic
medications produce improvement in the positive symptoms
of schizophrenia, they often result in serious adverse effects,
including extrapyramidal symptoms (EPS) (Schotte et al.
1996). Conventional antipsychotic medications have been
superseded by second-generation or atypical antipsychotics,
which are now the mainstay of pharmacotherapy for schizo-
phrenia (Sernyak and Rosenheck 2008). These newer
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agents, which are antagonists at dopamine D2 and
5-hydroxytryptamine 2A (5-HT2A) receptors, have demon-
strated antipsychotic efficacy and are generally associated
with a lower propensity for EPS than conventional antipsy-
chotics (Leucht et al. 2009a; Meltzer et al. 2003; Schotte et
al. 1996).
Most atypical antipsychotics display relatively high af-
finity for α1 adrenergic receptors, muscarinic receptors, and
H1 histaminergic receptors (Ishibashi et al. 2010; Kroeze et
al. 2003). The association of some atypical antipsychotics
with sedation, impairment in cognitive function, and weight
gain is thought to be due in part to effects at these receptors
(Ishibashi et al. 2010; Kroeze et al. 2003). In addition, some
atypical antipsychotics produce unfavorable changes in
plasma lipid levels and glucose metabolism (American
Diabetes Association et al. 2004; Henderson et al. 2005;
Newcomer 2007), and there is substantial variability among
atypical antipsychotics in the magnitude of weight gain and
metabolic changes resulting from treatment (Newcomer
2007).
The occurrence of adverse effects can negatively affect
treatment adherence. Results of a large, randomized,
double-blind study sponsored by the National Institute of
Mental Health showed that approximately 65 to 80 % of
outpatients with chronic schizophrenia discontinue their
antipsychotic medications, often because of lack of efficacy
or intolerable adverse effects (Lieberman et al. 2005). The
most common reasons for discontinuation because of intol-
erability were weight gain or metabolic effects, EPS, and
sedation. These observations underscore a need for addi-
tional treatment options for patients with schizophrenia.
Lurasidone is an atypical antipsychotic that was approved
by the US Food and Drug Administration (FDA) in October
2010 for the treatment of patients with schizophrenia
(Latuda® 2010). In vitro receptor binding studies and pre-
clinical behavioral studies indicate that lurasidone is an
antagonist with high affinity at D2, 5-HT2A, and 5-HT7
receptors; moderate affinity at human α2C adrenergic recep-
tors; and weak affinity at α2A adrenergic receptors (Ishiba-
shi et al. 2010). In addition, lurasidone acts as a partial
agonist at 5-HT1A receptors, with moderate to high affinity.
Notably, lurasidone exhibits no appreciable affinity for his-
tamine H1 and muscarinic M1 receptors (Ishibashi et al.
2010).
We report here the findings of the first in a series of
short-term, placebo-controlled studies conducted to as-
sess the efficacy and safety of lurasidone for the treat-
ment of schizophrenia (Nakamura et al. 2009; Meltzer
et al. 2011). This 6-week, randomized, double-blind,
placebo-controlled, phase 2 study evaluated the efficacy
and safety of two fixed, daily doses of lurasidone (40




The study enrolled men and women between 18 and 64 years
of age who met Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition (DSM-IV) criteria for primary diag-
nosis of schizophrenia as established by the Structured
Clinical Interview for DSM-IV Disorders–Clinician’s Ver-
sion (SCID-CV) (First et al. 1997) and were hospitalized for
an acute exacerbation of symptoms. Patients were also re-
quired to have illness duration of at least 1 year, no psychi-
atric hospitalization within the 3 months prior to study entry,
a Brief Psychiatric Rating Scale score derived (BPRSd)
from the Positive and Negative Syndrome Scale (PANSS)
of ≥42 (Guy 1976; Kay et al. 1987), a score of ≥4 on two or
more items of the positive symptoms subscale on the
PANSS, and a Clinical Global Impression of Severity
(CGI-S) score of ≥4 (moderate) (Guy 1976). Patients were
excluded if they had an acute or unstable medical condition;
a DSM-IV diagnosis of schizophreniform disorder, schizo-
affective disorder, or the catatonic or residual types of
schizophrenia; evidence of another chronic central nervous
system disorder; or an existing movement disorder. Patients
were also excluded if they had a history of resistance to
treatment with neuroleptics, defined as failure to respond to
two or more antipsychotic agents from two different classes,
or clozapine, administered at adequate doses for sufficient
duration, or had received depot antipsychotics within one
standard treatment cycle.
All patients provided written informed consent prior to
study enrollment. The study protocol and all related forms
and amendments were approved by an independent ethics
committee associated with each study center. The study was
conducted in accordance with FDA guidance documents on
Good Clinical Practice, as well as the International Confer-
ence on Harmonisation guidelines on Good Clinical Practices
(1996) and the ethical principles of the 1964 Declaration of
Helsinki.
Study design and treatment
This was a 6-week, multicenter, randomized, fixed-dose,
double-blind, parallel-group, placebo-controlled study con-
ducted at 16 sites in the USA between February and De-
cember 2001. The study included three periods: a screening
period of up to 14 days, a single-blind placebo washout
period of up to 7 days, and a 6-week double-blind treatment
period. Following the washout period, patients meeting
entry criteria were randomized, in a 1:1:1 ratio, to once-
daily fixed doses of lurasidone 40 mg, lurasidone 120 mg, or
placebo. Patients randomized to the 120-mg/day lurasidone
dose received 80 mg on day 1, and the dose was increased to
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120 mg by day 6. All patients remained in the hospital
during the screening and placebo washout periods and
through the first 2 to 4 weeks of the double-blind treatment
period. Patients with a Clinical Global Impression of Im-
provement (CGI-I) score of ≤4 were then eligible for dis-
charge from the hospital and continued study participation
as outpatients. Patients were discontinued from the study if
they did not show sufficient improvement to permit dis-
charge from the hospital by week 4 of the double-blind
treatment period.
Treatment compliance at each study visit was calculated
as the number of tablets taken (i.e., the number of tablets no
longer in the package) divided by the number of tablets that
should have been taken, multiplied by 100.
Concomitant medications
Benztropine mesylate or biperiden (1–2 mg twice daily)
were permitted for the treatment of EPS; prophylactic ad-
ministration of medications for EPS was prohibited. Lora-
zepam (up to 8 mg/day), zolpidem (up to 10 mg/day),
temazepam (up to 30 mg/day), or chloral hydrate (up to
1500 mg/day) were used as rescue medication for symptom
exacerbation. As-needed use of these concomitant medica-
tions was permitted for no more than five consecutive days
during the double-blind period until 8 hours prior to efficacy




The primary efficacy measure was the mean change on the
BPRSd score from baseline to week 6, assessed as the last
observation carried forward (LOCF). The BPRSd comprises
18 items (derived from the PANSS) rated on a scale of 10
not present to 70severe; therefore, the minimum possible
score is 18, and the maximum possible score is 126. Sec-
ondary efficacy measures included mean change from base-
line to week 6 (LOCF) on the PANSS total score, as well as
PANSS positive symptoms, negative symptoms, and general
psychopathology subscale scores (Lindenmayer et al. 1995);
the CGI-S (Guy 1976); and the CGI-I. All efficacy assess-
ments were completed at screening, at baseline, on days 3
and 7, and weekly thereafter (or on early termination).
Safety and tolerability
All adverse events volunteered or observed during the
study were recorded, together with their severity and
duration. Assessment of movement disorders occurred
at every study visit (or early termination) and included
administration of the 10-item Simpson-Angus Scale (SAS) to
evaluate parkinsonism (00normal to 40most severe) (Simp-
son and Angus 1970), the 4-item Barnes Akathisia Scale
(BAS) to evaluate akathisia (00normal to 50most severe)
(Barnes 1989), and the 12-item Abnormal Involuntary Move-
ment Scale (AIMS) to evaluate tardive dyskinesia (00normal
to 40most severe) (Guy 1976). Other safety measures includ-
ed 12-lead ECG, weight, vital signs, and clinical laboratory
assessments (hematology, serum chemistry, and urinalysis).
When possible, laboratory specimens were collected with
patients in the fasted state.
Statistical analysis
Allowing for a 10 % dropout rate prior to the first efficacy
assessment, it was estimated that 44 patients would be
needed per group (i.e., 132 patients total) to detect a stan-
dardized treatment difference of 0.730 between the lurasi-
done and placebo groups at 90 % power (two tailed) and at
an alpha level of 0.050 (two sided). A 35 % dropout rate
during the washout period was assumed. Therefore, it was
planned to enter approximately 205 patients into the placebo
washout period to ensure that 132 patients were randomized
into the study.
Efficacy analyses were performed using the intent-to-
treat (ITT) population, which consisted of all random-
ized patients who received at least one dose of study
medication at the daily dose for the group (i.e., 40 mg
lurasidone, 120 mg lurasidone, or placebo) and had at
least one efficacy evaluation on or after day 3. Ob-
served case analyses were also conducted for the pri-
mary and secondary efficacy measures, with completers
represented by observed cases at day 42. The safety
population comprised all patients who received at least
one dose of study medication and was used for all
safety analyses.
Comparisons among treatment groups at baseline
were performed using a one-way analysis of variance,
with treatment as a term in the model. For the primary
efficacy measure of change from baseline to week 6
(LOCF) on the BPRSd, an analysis of covariance
(ANCOVA) model was used with effects for center,
treatment, and center-by-treatment interaction, and base-
line BPRSd as the covariate. If the center-by-treatment
interaction was not significant (p≥0.10), it was removed
from the model. If the overall ANCOVA of the
baseline-to-endpoint change score was significant, pair-
wise comparisons were performed using a Dunnett
t test. The type I error rate for rejecting a null hypoth-
esis was set at 0.050 (two sided) for both the ANCOVA
and the Dunnett test.
Secondary efficacy measures of change from baseline in
the PANSS total and subscale scores, CGI-S, and CGI-I,
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were analyzed using ANCOVA models. The interaction
term was excluded from the PANSS and CGI-I models.
Patients with a reduction of ≥20 % from baseline in
BPRSd or with a CGI-I score of 1 or 2 were classified as
treatment responders. The proportion of responders versus
nonresponders was compared using a Cochran–Mantel–
Haenszel test controlling for center. Cohen’s d treatment
effect sizes were calculated for primary and secondary effi-
cacy measures as the difference in least-squares (LS) mean
change score for lurasidone (40 or 120 mg/day) and placebo
(LOCF) divided by the pooled standard deviation.
For safety analyses, all statistical tests were two-sided at
an alpha level of 0.05. One-way ANCOVA was used to
analyze changes from baseline in the composite (total score)
SAS, BAS, and AIMS scores. The Fisher exact test was
used for between-group comparisons of the rates of adverse
events.
Results
Of 223 patients who were screened, 149 met entry
criteria at the end of the washout period and were
randomized to double-blind treatment (50 to lurasidone
40 mg/day, 49 to lurasidone 120 mg/day, and 50 to
placebo) (Fig. 1). Baseline characteristics were similar
across treatment groups (Table 1). The majority of
patients in each group were men who met criteria for
the paranoid subtype of schizophrenia. The ITT popula-
tion, used for efficacy analyses, included 49 patients
assigned to lurasidone 40 mg/day, 47 assigned to lura-
sidone 120 mg/day, and 49 assigned to placebo. All
randomized patients were included in the safety popula-
tion. Overall, 51 patients completed the study: 16
(32.0 %) in the 40 mg/day group, 20 (40.8 %) in the
120-mg/day group, and 15 (30.0 %) in the placebo
group. The most common reason for discontinuation
was withdrawal of consent (24.8 % of randomized
patients across all treatment groups) (Fig. 1). Lack of
efficacy was the most common reason for discontinua-
tion in the placebo group (32.0 %) and was cited less
frequently as a reason for discontinuation in the 40
(22.0 %) and 120 mg/day lurasidone (12.2 %) groups.
The placebo group had the lowest rate of discontinua-
tion due to adverse events (4.0 %), whereas rates were
higher and similar for the 40 (12.0 %) and 120 mg/day
lurasidone (12.2 %) groups.
Study treatment
The mean (standard deviation) duration of exposure to
study treatment was similar among patients randomized
to lurasidone 40 mg/day (23.4 (15.9) days), lurasidone
120 mg/day (23.0 (16.7) days), or placebo (22.2 (15.8)
days). Mean treatment compliance was 97.5, 99.5, and
98.9 % for the lurasidone 40 mg/day, lurasidone
120 mg/day, and placebo groups, respectively. The ma-
jority of patients received benzodiazepines at least once
during the study: 90.0 % of patients in the lurasidone
40 mg/day group, 87.8 % in the lurasidone 120 mg/day
group, and 82.0 % in the placebo group. The mean
daily dose of lorazepam was calculated by week and
ranged from 0.5 to 1.3 mg for patients receiving lur-
asidone 40 mg/day, 0.9 to 1.7 mg for patients receiving
lurasidone 120 mg/day, and 1.2 to 2.6 mg for patients
receiving placebo.
Efficacy
The LS mean change in BPRSd score (primary efficacy
measure) from baseline to week 6 (LOCF) was signifi-
cantly greater with lurasidone 40 (−9.4; p00.018 versus
placebo) and 120 mg/day (−11.0; p00.004 versus pla-
cebo) compared with placebo (−3.8) (Fig. 2). Results
for completers (observed cases at day 42) are also
shown in Fig. 2. Patients who completed treatment with
lurasidone had numerically larger decreases in BPRSd
scores than the overall LOCF analysis sample; however,
there were no significant differences from placebo for
either dose group for completers at day 42, perhaps as a
result of small sample size.
For the PANSS total score (secondary efficacy mea-
sure), the LS mean change from baseline to week 6
(LOCF) was significantly greater in the lurasidone
120 mg/day group compared with placebo (p00.009),
and a trend toward significance was noted for the lur-
asidone 40 mg/day group (p00.076) (Table 2). Both
lurasidone doses were significantly better than placebo
with regard to improvement from baseline in PANSS
positive symptoms score, CGI-S, and CGI-I. Patients
receiving lurasidone 120 mg/day (but not 40 mg/day)
also exhibited significantly greater improvement than
those receiving placebo in PANSS negative symptoms
and general psychopathology scores. Compared with the
overall sample, study completers showed greater im-
provement with lurasidone (40 or 120 mg/day) relative
to placebo on each PANSS and CGI measure, but dif-
ferences failed to reach statistical significance (data not
shown).
The proportion of treatment responders based on a ≥20 %
decrease from baseline in BPRSd score at week 6 (LOCF)
was significantly higher for the lurasidone 40 (51.0 %) and
120 mg/day (44.7 %) treatment groups compared with the
placebo group (18.4 %; p<0.005 for both comparisons)
(Fig. 3). Similarly, a greater proportion of patients in the
lurasidone 40 (36.7 %) and 120 mg/day (30.4 %) groups had
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a CGI-I score of 1 or 2 (very much or much improved) at
week 6 (LOCF) compared with patients in the placebo
group (12.2 %; p<0.05 for both comparisons). The effect
size (LOCF) on the BPRSd was 0.53 for lurasidone 40 mg/
day and 0.65 for lurasidone 120 mg/day. Effect sizes for
secondary efficacy measures are shown in Table 2.
Fig. 1 Study flow diagram
Table 1 Summary of patient characteristics at baseline (safety population)
Characteristic Lurasidone (40 mg/day; N050) Lurasidone (120 mg/day; N049) Placebo (N050)
Sex (male; n (%)) 36 (72.0) 36 (73.5) 42 (84.0)
Race (n (%))
White 20 (40.0) 22 (44.9) 20 (40.0)
Black 25 (50.0) 24 (49.0) 25 (50.0)
Other 5 (10.0) 3 (6.1) 5 (10.0)
Age (years; mean (SD)) 39.8 (9.5) 41.0 (9.0) 38.1 (9.7)
Body mass index (kg/m2; mean (SD)) 29.5 (7.3) 29.6 (7.6) 29.4 (5.6)
Schizophrenia subtype (n (%))
Paranoid 45 (90.0) 44 (89.8) 45 (90.0)
Undifferentiated 4 (8.0) 4 (8.2) 4 (8.0)
Disorganized 1 (2.0) 0 (0.0) 1 (2.0)
BPRSd
Mean (SD) 54.6 (9.1) 52.5 (7.6) 54.4 (8.3)
Median (range) 53.0 (41.0–73.0) 52.0 (38.0–72.0) 53.5 (39.0–74.0)
PANSS total (mean (SD)) 92.8 (16.1) 89.6 (13.4) 93.3 (16.4)
CGI-S (mean (SD)) 4.8 (0.7) 4.7 (0.6) 4.6 (0.7)
Differences among treatment groups for sex, race, and schizophrenia subtype were assessed using a Fisher exact test; differences for age, body mass
index, BPRSd, PANSS, and CGI-S were assessed using analysis of variance with treatment in the model; differences in prior medications were not
evaluated statistically. All available tests were not significant (p>0.25)
BPRSd Brief Psychiatric Rating Scale (derived from the PANSS), CGI-S Clinical Global Impression of Severity, PANSS Positive and Negative
Syndrome Scale, SD standard deviation
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Tolerability and safety
Adverse events
The rate of adverse events occurring in ≥5 % of patients
is summarized in Table 3. The most commonly reported
adverse events for patients receiving lurasidone were
nausea (16.2 %), sedation (16.2 %), akathisia
(11.1 %), dizziness (11.1 %), and headache (11.1 %).
More patients receiving lurasidone 120 mg/day reported
nausea and akathisia (22.4 and 14.3 %, respectively)
than those receiving lurasidone 40 mg/day (10.0 and
8.0 %, respectively). The majority of adverse events
were mild to moderate in intensity. The frequency of
adverse events classified as severe was similar (6.0–
6.1 %) for the lurasidone and placebo groups.
An adverse event was cited as the reason for early
treatment discontinuation for 14 patients: six (12.0 %)
patients receiving lurasidone 40 mg/day, six (12.2 %)
patients receiving lurasidone 120 mg/day, and two
(4.0 %) patients receiving placebo. The most common
adverse events leading to discontinuation were worsen-
ing of schizophrenia or other psychosis (n05), move-
ment disorder symptoms (n03), and elevations in
prolactin level (n02). Serious adverse events were
reported for four patients (8.0 %) receiving lurasidone
40 mg/day, two patients (4.1 %) receiving lurasidone
120 mg/day, and four patients (8.0 %) receiving place-
bo, all of which were exacerbations of schizophrenia or
other psychosis. No patients died during the study.
Extrapyramidal symptoms
Change from baseline to week 6 (LOCF) on measures of
EPS and use of concomitant anticholinergic medication are
shown in Table 4. There were no significant differences
among treatment groups at any time point for mean SAS
and AIMS scores. However, there were significant differ-
ences favoring lurasidone 40 compared with 120 mg/day in
mean BAS scores (change from baseline) at week 2 (lurasi-
done 40 mg/day, −0.3; lurasidone 120 mg/day, 1.4; and
placebo, −0.3; p00.013), week 4 (lurasidone 40 mg/day,
0.0; lurasidone 120 mg/day, 1.9; and placebo, −0.6; p0
0.003), and week 5 (lurasidone 40 mg/day, −0.4; lurasidone
120 mg/day, 1.0; and placebo, −0.3; p00.047) but not at
week 6 LOCF endpoint (p00.490). Movement disorder
adverse events reported more frequently in patients receiv-
ing lurasidone 40 and 120 mg/day versus placebo, respec-
tively, included tremor (6.0 and 8.2 versus 0.0 %), muscle
cramps (2.0 and 6.1 versus 0.0 %), extrapyramidal disorder
(4.0 and 6.1 versus 0.0 %), and akathisia (8.0 and 14.3
versus 0.0 %). Three patients discontinued the study be-
cause of EPS or akathisia: one patient in the lurasidone
40 mg/day group and two patients in the lurasidone
120 mg/day group. The proportion of patients receiving
concomitant benztropine for the treatment of movement
disorders was higher in the lurasidone groups (24.0 % with
40 mg/day and 24.5 % with 120 mg/day) than in the placebo
group (18.0 %) (Table 4).
Body weight
There were minimal changes in mean body weight in any
treatment group at week 6 (LOCF) (Table 5).
Metabolic and other laboratory tests
Change in median total cholesterol from baseline to
week 6 LOCF endpoint was comparable for patients
treated with lurasidone (−13 mg/dL for lurasidone
40 mg/day and −3 mg/dL for lurasidone 120 mg/day)
and patients in the placebo group (−11.0 mg/dL)
(Table 5). Median triglyceride levels remained un-
changed in the lurasidone 40 mg/day group, increased by
16.5 mg/dL from baseline to week 6 LOCF endpoint in the
lurasidone 120 mg/day group, and decreased by −11 mg/dL in
the placebo group (Table 5). Median serum glucose levels
were either unchanged or minimally decreased from baseline
to week 6 LOCF endpoint in all groups (Table 5). There were
no clinically significant hematology laboratory test results or
urinalysis results reported. Clinically significant markedly
abnormal chemistry values were observed in one patient tak-
ing lurasidone 120 mg/day (elevated alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and triglycerides),
Fig. 2 Change from baseline in BPRSd score. Least-squares (LS)
mean change from baseline in BPRSd score. Analysis of covariance
model with baseline value as covariate. Comparison with placebo
based on a two-sided Dunnett t test and based on last observation
carried forward (LOCF) analysis. *p<0.05; †p<0.01. BPRSd Brief
Psychiatric Rating Scale (derived from the PANSS), PANSS Positive
and Negative Syndrome Scale. Circles, placebo, n049 (LOCF), n017
(day 42); squares, lurasidone 40 mg, n049 (LOCF), n017 (day 42);
diamonds, lurasidone 120 mg, n047 (LOCF), n019 (day 42)
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and one patient in the placebo group (elevated ALTand AST).
For one patient randomized to lurasidone 40 mg/day, hyper-
glycemia of 3+ glucosuria and elevated ALTwere observed at
baseline, prior to the first dose of study medication.
Prolactin
Median prolactin levels at week 6 LOCF endpoint were
modestly increased relative to baseline in the lurasidone 40
(3.5 ng/mL) and 120 mg/day (7.7 ng/mL) groups but not in
the placebo group (−1.3 ng/mL) (Table 5). A sex difference
was observed, with lurasidone producing greater increases
in prolactin in women than in men. Among women, the
median change in prolactin at week 6 LOCF endpoint was
3.8 ng/mL in the lurasidone 40 mg/day group, 21.1 ng/mL
in the lurasidone 120 mg/day group, and 0.4 ng/mL in the
placebo group. Among men, smaller median changes in
prolactin were observed in the lurasidone 40 (3.4 ng/mL)
and 120 mg/day (5.6 ng/mL) treatment groups; the median
prolactin level in the placebo group decreased by 1.4 ng/mL.
Two patients (one female patient in the lurasidone 40 mg/
day group and one female patient in the lurasidone 120 mg/
day group) discontinued the study because of elevated pro-
lactin based on predetermined elevations (>200 ng/mL). No
prolactin-related clinical symptoms (e.g., galactorrhea) were
observed.
Table 2 Change from baseline
to week 6 (LOCF) in efficacy
measures (intent-to-treat
population)
Analysis of covariance models
based on last observation carried
forward with center and treat-
ment as effects and baseline
value as covariate
Comparison with placebo was
performed using a two-sided,
0.050 Dunnett t test
BPRSd Brief Psychiatric Rating
Scale (derived from the
PANSS), CGI-I Clinical Global
Impression of Improvement,
CGI-S Clinical Global Impression
of Severity, CI confidence
interval, LS least-squares, PANSS
Positive and Negative Syndrome
Scale, SE standard error






LS mean change (SE) −9.4 (1.6) −11 (1.6) −3.8 (1.6)
LS mean difference (SE) −5.6 (2.1) −6.7 (2.2)
Effect size 0.53 0.65
p value 0.018 0.004
PANSS total score
LS mean change (SE) −14 (2.7) −17 (2.7) −6.2 (2.7)
LS mean difference (SE) −7.6 (3.7) −11 (3.7)
Effect size 0.42 0.60
p value 0.076 0.009
PANSS positive symptoms
LS mean change (SE) −4.6 (0.8) −5.1 (0.8) −1.8 (0.8)
LS mean difference (SE) −2.8 (1.1) −3.3 (1.1)
Effect size 0.53 0.63
p value 0.018 0.005
PANSS negative symptoms
LS mean change (SE) −2.7 (0.8) −4.0 (0.8) −1.0 (0.8)
LS mean difference (SE) −1.7 (1.0) −2.9 (1.1)
Effect size 0.33 0.56
p value 0.177 0.011
PANSS general psychopathology
LS mean change (SE) −5.8 (1.5) −7.8 (1.5) −2.5 (1.5)
LS mean difference (SE) −3.3 (2.0) −5.3 (2.1)
Effect size 0.33 0.53
p value 0.185 0.023
CGI-S
LS mean change (SE) −0.8 (0.2) −0.8 (0.1) −0.1 (0.1)
LS mean difference (SE) −0.7 (0.2) −0.7 (0.2)
Effect size 0.67 0.68
p value 0.002 0.001
CGI-I
LS mean (SE) 3.3 (0.2) 3.2 (0.2) 4.1 (0.2)
LS mean difference (SE) −0.8 (0.3) −0.9 (0.3)
Effect size 0.62 0.68
p value 0.006 0.002
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Physical examination and vital signs
There were no clinically significant differences between
lurasidone (40 or 120 mg/day) and placebo in changes in
vital signs at any assessment.
Electrocardiogram
Treatment with lurasidone was not associated with any
clinically significant treatment-emergent ECG abnormal-
ities. The results of ECG were comparable at all assess-
ments. The mean QT interval corrected (QTc) was
slightly decreased (−3.3 ms) in the lurasidone
120 mg/day group and showed a small mean increase
in both lurasidone 40 mg/day (3.0 ms) and placebo
(2.2 ms) groups (Table 5), but changes from baseline
were not clinically meaningful. No patients in any of
the three treatment groups had an increase in QTc
interval of >60 ms. One patient, a 56-year-old woman
in the placebo group, discontinued due to nonspecific
ST-T segment ECG abnormalities.
Discussion
This was a phase 2 placebo-controlled study of lurasidone
conducted in patients with schizophrenia and, as such, it
included a limited sample size and was exploratory in na-
ture. The study was not statistically powered to detect treat-
ment effect sizes of the magnitude typically seen in placebo-
controlled studies of atypical antipsychotic medications
(Leucht et al. 2009b). Nonetheless, the results of this study
Fig. 3 Rates of treatment response. Proportion of patients classified as
treatment responders based on a reduction of ≥20 % from baseline to
week 6 (LOCF) in BPRSd score. Lurasidone 40 mg/day (n049);
lurasidone 120 mg/day (n047); and placebo (n049). *p<0.01 com-
pared with placebo. BPRSd Brief Psychiatric Rating Scale (derived
from the PANSS), LOCF last observation carried forward, PANSS
Positive and Negative Syndrome Scale
Table 3 Treatment-emergent
adverse events occurring at a
rate of ≥5 % for any dose of
lurasidone (safety population)
Comparison with placebo was
performed using Fisher exact
test
NOS not otherwise specified
*p<0.05 versus placebo






Any adverse event 40 (80.0) 38 (77.6) 36 (72.0)
Nausea 5 (10.0) 11 (22.4)* 2 (4.0)
Sedation 9 (18.0) 7 (14.3) 5 (10.0)
Headache NOS 8 (16.0) 3 (6.1) 5 (10.0)
Akathisia 4 (8.0) 7 (14.3)* 0 (0)
Dizziness excluding vertigo 6 (12.0) 5 (10.2) 3 (6.0)
Dyspepsia 4 (8.0) 2 (4.1) 6 (12.0)
Somnolence 4 (8.0) 5 (10.2) 2 (4.0)
Vomiting NOS 4 (8.0) 4 (8.2) 3 (6.0)
Fatigue 4 (8.0) 1 (2.0) 4 (8.0)
Tremor 3 (6.0) 4 (8.2) 0 (0)
Insomnia 3 (6.0) 4 (8.2) 0 (0)
Diarrhea 3 (6.0) 0 (0) 4 (8.0)
Constipation 4 (8.0) 0 (0) 3 (6.0)
Back pain 2 (4.0) 3 (6.1) 1 (2.0)
Extrapyramidal disorder 2 (4.0) 3 (6.1) 0 (0)
Pain in limb 3 (6.0) 1 (2.0) 1 (2.0)
Muscle cramp 1 (2.0) 3 (6.1) 0 (0)
Any adverse event reported as severe 3 (6.0) 3 (6.1) 3 (6.0)
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indicate that lurasidone, at fixed daily doses of 40 and 120 mg
administered for 6 weeks, was an effective treatment for
patients experiencing an acute exacerbation of chronic schizo-
phrenia, with treatment effect sizes comparable to or greater
than those in other clinical studies of atypical antipsychotics
(Leucht et al. 2009b). Lurasidone 40 and 120 mg/day pro-
duced significantly greater improvement than placebo on the
primary efficacy measure, the change from baseline to week 6
(LOCF) in BPRSd score. On secondary efficacy measures,
treatment with lurasidone 40 or 120 mg/day resulted in signif-
icantly greater improvement than placebo in PANSS positive
symptoms scores, CGI-S, and CGI-I. The 120 mg/day dose
also provided significant improvement in PANSS total, nega-
tive symptoms, and general psychopathology scores. The
proportion of treatment responders was similar in the lurasi-
done 40 and 120 mg/day groups and was significantly greater
than in the placebo group.
Findings from this study have been replicated and extended
in a larger (N0478) phase 3 study with a similar patient
population (Meltzer et al. 2011). This 6-week, randomized,
double-blind, placebo-controlled study also included olanza-
pine as an active comparator to confirm assay sensitivity.
Table 4 Change in extrapyramidal symptom scores and use of concomitant anticholinergic medication (safety population)
Lurasidone (40 mg/day; N050) Lurasidone (120 mg/day; N049) Placebo (N050)a
Scale (mean (SD) change)
SAS 0.1 (1.2) 0.0 (1.1) −0.1 (0.9)
BAS 0.3 (2.9) 0.8 (2.7) 0.1 (2.6)
AIMS 0.6 (2.8) 0.3 (2.4) 0.7 (2.6)
Use of as-needed concomitant anticholinergic medication (n (%))
Benztropineb 12 (24.0) 12 (24.5) 9 (18.0)
Change from baseline in SAS, BAS, and AIMS was analyzed using one-way analysis of covariance
SD standard deviation, SAS Simpson–Angus Scale, BAS Barnes Akathisia Scale, AIMS Abnormal Involuntary Movement Scale
a One to two missing values for scales
b No other antiparkinson drugs were reported
Table 5 Change from baseline
to week 6 (LOCF) in key safety
parameters
When possible, blood samples
for evaluation of lipid, glucose,
and prolactin levels were col-
lected with patients in the fasted
state
QTc interval QT interval cor-











Mean (SD) baseline value 87.4 (22.0)a 90.2 (25.7)b 89.3 (20.2)b
Mean (SD) change 0.3 (2.2) 0.2 (2.6) 0.0 (2.9)
Total cholesterol (mg/dL)
Mean (SD) baseline value 212 (45.8)c 194 (62.8)d 219 (38.9)c
Median change −13.0 −3.0 −11.0
Triglycerides (mg/dL)
Mean (SD) baseline value 190 (137)c 272 (379)d 275 (187)c
Median change 0.0 16.5 −11.0
Serum glucose (mg/dL)
Mean (SD) baseline value 105 (42.0)c 113 (46.8)d 98.1 (19.2)c
Median change 0.0 −2.0 −0.5
Prolactin (ng/mL)
Mean (SD) baseline value 9.0 (4.7)c 10.8 (8.0)d 14.8 (23.7)c
Median change 3.5 7.7 −1.3
QTc interval
Mean (SD) baseline value (ms) 421.2 (20.0) 420.8 (24.5)a 416.8 (20.0)
Mean (SD) change (ms) 3.0 (23.6) −3.3 (19.9) 2.2 (21.2)
Increase of >60 ms (n (%)) 0 (0) 0 (0) 0 (0)
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Results demonstrated that lurasidone 40 and 120 mg/day
produced significantly greater improvement than placebo in
PANSS total score (the primary outcome measure), PANSS
subscale scores, and CGI-S score (Meltzer et al. 2011). Based
on a post-hoc analysis, there were no significant differences in
efficacy for lurasidone versus olanzapine (Meltzer et al. 2011).
In the present study, lurasidone 120 mg/day significantly
improved PANSS total score (secondary measure) compared
with placebo (p00.009), and a trend toward significance
was observed for lurasidone 40 mg/day (p00.076). The
ability to detect a significant effect for lurasidone 40 mg/
day on PANSS total score may have been limited by the
relatively small sample size in this study.
The efficacy of lurasidone in the treatment of schizophrenia
was also demonstrated in a study that evaluated an intermedi-
ate dose, 80 mg/day, for the treatment of schizophrenia
(Nakamura et al. 2009). In that 6-week, randomized, double-
blind, placebo-controlled study (N0180), patients receiving
lurasidone 80 mg/day showed significantly greater improve-
ment from baseline to week 6 (LOCF) in BPRSd (primary
measure) than patients receiving placebo (Nakamura et al.
2009). Lurasidone 80 mg/day also produced significantly
greater improvement than placebo on secondary measures,
including the PANSS total score, PANSS subscale scores
(positive, negative, cognitive, and general psychopathology
subscales), and CGI-S (Nakamura et al. 2009).
Metabolic adverse effects associated with atypical anti-
psychotic therapy, including weight gain and changes in
lipid and glucose levels, are a cause of substantial concern.
Treatment with atypical antipsychotic medications has been
linked to increased risk of obesity, diabetes, and dyslipide-
mia for patients with schizophrenia (American Diabetes
Association 2004). According to a meta-analysis including
head-to-head comparisons of nine atypical antipsychotic
medications (amisulpride, aripiprazole, clozapine, olanza-
pine, quetiapine, risperidone, sertindole, ziprasidone, and
zotepine), some agents were associated with considerably
greater weight gain and metabolic adverse effects than
others (Rummel-Kluge et al. 2010). Specifically, clozapine
and olanzapine produced the greatest elevations in weight,
cholesterol, and glucose. Quetiapine, risperidone, and ser-
tindole showed intermediate elevations in these metabolic
parameters. Aripiprazole, amisulpride, and ziprasidone were
associated with small changes in weight and metabolic
indices (Rummel-Kluge et al. 2010).
An important finding of the current study is that lurasidone
had minimal effects on body weight and other metabolic
parameters. Mean weight change from baseline was small
and consistent with other studies of lurasidone (Meltzer et al.
2011; Nakamura et al. 2009). Other metabolic indices, includ-
ing cholesterol, triglyceride, and glucose levels, either de-
creased or remained essentially unchanged, as has been
reported in other studies of lurasidone (Meltzer et al. 2011;
Nakamura et al. 2009; Potkin et al. 2011). Together, these
findings suggest that the clinically significant weight gain and
metabolic changes observed during short-term treatment with
some atypical antipsychotics (Leucht et al. 2009a) are unlikely
to occur with lurasidone. Lurasidone’s low propensity for
weight gain and minimal effect on glucose and lipid parame-
ters may be an important treatment consideration, especially in
light of the increased rate of metabolic syndrome among
patients with schizophrenia (Correll et al. 2010; Newcomer
2007). Lurasidone may be a particularly appropriate treatment
for patients who are concerned about the potential for weight
gain, dyslipidemia, and hyperglycemia during antipsychotic
treatment.
Adverse events observed in the present study were gen-
erally comparable with those that have been previously
reported in other studies of lurasidone (Meltzer et al. 2011;
Nakamura et al. 2009). Most adverse events were rated as
mild to moderate in intensity. The proportion of patients
who experienced adverse events rated as severe was low
and comparable for lurasidone and placebo (6.0–6.1 %).
Lurasidone appeared to be better tolerated at 40 than
120 mg/day in the present study. Nausea was more common
among patients treated with lurasidone 120 mg/day com-
pared with 40 mg/day. Although results of this study suggest
that treatment with lurasidone at doses of 40 and 120 mg/
day has a low propensity for causing EPS, the occurrence of
akathisia appeared to be dose related. Treatment with lura-
sidone resulted in modest, dose-dependent increases in pro-
lactin levels, which were more pronounced in female
patients. Similar increases in prolactin were observed with
lurasidone treatment in other short-term studies (Meltzer et
al. 2011; Nakamura et al. 2009; Potkin et al. 2011). The
mean increase in prolactin levels observed with lurasidone
120 mg/day was lower than that reported following short-
term treatment with risperidone, paliperidone, or conven-
tional antipsychotics (Bostwick et al. 2009). No galactor-
rhea or other clinically important prolactin-related adverse
events were reported in this study.
Limitations of the current study include the short duration,
small sample size, and high rate of discontinuation, which
make it difficult to draw firm conclusions about the treatment
effects of lurasidone. The all-cause discontinuation rate was
59 to 68% for patients treated with lurasidone and 70% in the
placebo group. The average all-cause discontinuation rate in
short-term (4- to 12-week) placebo-controlled studies of atyp-
ical antipsychotics is 48 % for active treatment and 60 % for
placebo (Kemmler et al. 2005). In contrast to the present
study, other studies of lurasidone had lower-than-average rates
of discontinuation (Meltzer et al. 2011; Nakamura et al. 2009).
All-cause discontinuation rates in a larger 6-week study of
lurasidone 40 and 120mg/daywere 36 and 45%, respectively,
compared with 39 % for placebo (Meltzer et al. 2011). In the
present study, the protocol required that patients must be
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discontinued from study participation if they had not im-
proved enough by week 4 to permit hospital discharge, which
may have contributed to the relatively high rates of discontin-
uation due to lack of efficacy. Since this was an early study of
a novel medication, investigators may have had concerns
about the efficacy and tolerability of the investigational med-
ication, leading to higher discontinuation rates than observed
in subsequent studies and increased use of rescuemedications.
Supporting this view, use of benzodiazepines occurred at
similar high rates in the lurasidone and placebo groups.
In conclusion, this study, which was limited by a relatively
high rate of discontinuation, suggests that short-term adminis-
tration of lurasidone in doses of 40 or 120 mg/day was effec-
tive in the treatment of patients experiencing an acute
exacerbation of chronic schizophrenia. Treatment with lurasi-
done had minimal effects on weight and metabolic parameters.
Lurasidone may offer an effective once-daily treatment with
few metabolic complications for patients with schizophrenia.
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